Amundi Sells 360,913 Shares of Charles River Laboratories International, Inc. $CRL

Amundi trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 46.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 412,402 shares of the medical research company's stock after selling 360,913 shares during the period. Amundi owned 0.86% of Charles River Laboratories International worth $93,529,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in Charles River Laboratories International by 22,535.2% during the 2nd quarter. California State Teachers Retirement System now owns 12,895,733 shares of the medical research company's stock valued at $2,924,623,000 after acquiring an additional 12,838,761 shares during the period. Invesco Ltd. boosted its stake in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company's stock worth $537,828,000 after acquiring an additional 1,446,972 shares in the last quarter. State Street Corp grew its holdings in Charles River Laboratories International by 2.2% in the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company's stock worth $373,364,000 after purchasing an additional 40,535 shares during the period. Dimensional Fund Advisors LP grew its holdings in Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after purchasing an additional 210,260 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company's stock valued at $254,186,000 after purchasing an additional 9,756 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling

In other news, EVP Victoria Creamer sold 4,179 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president directly owned 30,051 shares of the company's stock, valued at $7,788,017.16. This represents a 12.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James Foster sold 33,561 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at approximately $9,478,800. This trade represents a 51.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 165,990 shares of company stock valued at $42,606,388 in the last ninety days. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Down 0.9%

Charles River Laboratories International stock opened at $278.36 on Thursday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $303.30. The stock has a market capitalization of $13.29 billion, a PE ratio of -57.39, a price-to-earnings-growth ratio of 2.75 and a beta of 1.40. The business's fifty day moving average is $258.38 and its 200 day moving average is $204.34.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter in the previous year, the firm earned $3.12 EPS. Charles River Laboratories International's revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on CRL shares. Barclays reissued an "overweight" rating and issued a $300.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Mizuho set a $264.00 price objective on Charles River Laboratories International in a research report on Monday, August 10th. Weiss Ratings upgraded Charles River Laboratories International from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 1st. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $259.44.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.